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Summary
Differentially expressed genes in various benign and malig-
nant salivary gland tumours were identified by use of cDNA
microarrays containing 19,000 human expressed sequence
tags. Samples were derived from 5 patients with pleomor-
phic adenoma, 4 with Warthin’s tumour, one with clear cell
carcinoma, and 2 with mucoepidermoid carcinoma.
Tumours were classified by using a subset of 486 genes.
Benign Warthin’s tumour and pleomorphic adenoma showed
very distinctive gene expression patterns. A total of 133
genes differentiated the single malignant clear cell carci-
noma from non-tumour salivary glands (p < 0.01), whereas
only 16 genes separated it from the highly related benign
pleomorphic adenoma (p < 0.01). A total of 57 cDNAs were
associated with mucoepidermoid carcinoma (p < 0.01). The
results show gene expression alterations common to all
tumours and unique to each benign and malignant tumour.
The numerous Expressed Sequence Tags of unknown func-
tion we identified could also become useful as tumour
markers and represent a set of novel tumour-associated
genes.
Riassunto
Sono stati identificati con l’uso di cDNA microarrays conte-
nenti 19.000 sequenze geniche, differenti geni espressi in tu-
mori benigni e maligni delle ghiandole salivari. I campioni so-
no stati ricavati da 5 pazienti affetti da adenoma pleomorfo, 4
da tumori di Warthin, 1 con carcinoma a cellule chiare e 2 con
carcinoma muco-epidermoidale. Questi tumori sono stati clas-
sificati usando un subset di 486 geni. Il tumore di Warthin e
l’adenoma pleomorfo hanno mostrato un pattern di espressio-
ne genica estremamente tipico. Il campione di carcinoma a
cellule chiare ha dimostrato 133 geni differenti rispetto al tes-
suto salivare normale (p < 0.01), solo 16 geni lo differenziano
dall’adenoma pleomorfo (p < 0.01), mentre 57 geni erano as-
sociati al carcinoma muco epidermoidale (p < 0.01). Questi ri-
sultati dimostrano che esistono alterazioni dell’espressione
genica comuni a tutti i tumori e altre esclusive per i tumori be-
nigni e/o maligni. Sono stati anche identificati numerosi
Espressed Sequence Tags, la cui funzionalità è ancora scono-
sciuta e che potrebbero essere usati come marker tumorali e
rappresentare un nuovo gruppo di geni tumore associati.
Introduction
Pleomorphic adenoma is the most common benign
tumour of major salivary glands. Cytogenetic analy-
ses have recognized, in addition to a subgroup with
normal karyotypes, recurrent chromosomal translo-
cations, with breakpoints at 8q12, 3p21, and 12q13-
15 1 and corresponding to PLAG1 2, β-catenin
(CTNNB1) 3, and HMGIC 4 genes, respectively. The
second most common benign lesion of the salivary
glands is Warthin’s tumour. It consists of lymphoid
stroma and oncocytic epithelium that form cystic or
papillary structures. The epithelial component rep-
resents the neoplastic proliferation of salivary ducts
that have been entrapped within the lymph nodes
associated with the salivary gland. Mucoepidermoid
carcinoma is the most common malignant, locally
invasive tumour of the salivary glands, especially of
the parotid gland. Some markers of tumour progres-
sion, invasiveness, and prognosis are p21(Kip1), a
cyclin-dependent kinase inhibitor, the oncoproteins
Bcl-2 and Bax, the tumour suppressor gene product
p53, terminal deoxynucleotidyltransferase-mediat-
ed nick end labelling staining, and the cell cycle
antigen Ki-67 5 6. Clear cell carcinoma is a rare form
of malignant tumour occurring more often in pleo-
morphic adenoma. This tumour shows definite areas
characteristic of pleomorphic adenoma combined
with areas revealing evidence of malignancy. With
the technology of cDNA microarrays, it is possible
 to make a comparative analysis of mRNA expres-
sion of thousands of genes in parallel 7. Several
studies have already demonstrated the usefulness of
this technique for identifying novel cancer-related
genes and for classifying human cancer at molecu-
lar level 8-10. In this study, a cDNA microarray has
been used containing 19,200 different human
probes corresponding to different Unigene clusters
to characterize benign and malignant salivary gland
tumours.
Material and Methods
PATIENTS AND TISSUE SPECIMENS
Samples were obtained from surgically resected
parotid tissue from 5 patients with pleomorphic ade-
noma, 4 with Warthin’s tumour, one with clear cell
carcinoma, and two with mucoepidermoid carcino-
ma. Informed consent was obtained from patients to
use the surgical specimens for research purposes.
Part of each sample was frozen in liquid nitrogen and
stored at -80°C until RNA extraction, and the remain-
der was used for histopathological analysis. Tumour
paired control, non-tumour, tissues were obtained
from a clinically unaffected site and were histologi-
cally normal.
MICROARRAY ASSAYS
Total RNA was extracted from the biopsies using
RNAzol. Ten µg of total RNA were used for each
sample. cDNA was synthesized using Superscript II
(Life Technologies, Inc.) and amino-allyl dUTP (Sig-
ma). Monoreactive Cy3 and Cy5 esters (Amersham
Pharmacia) were used for indirect cDNAlabelling. A
pool of 8 non-tumour salivary gland RNA was la-
belled with Cy3 and used as a control against the
Cy5-labelled tumour cDNA. Human 19.2 K DNA
microarrays, containing ESTs3 corresponding to at
least 15,448 different Unigene clusters, were used
(Ontario Cancer Institute) 3. One hundred µl of the
sample and control cDNAin DIG Easy hybridization
solution (Roche) were used in a sandwich hybridiza-
tion of the two slides constituting the 19.2 K set at 37
°C overnight. Washing was performed 3 times for 10
min with 1-SSC, 0.1% SDS at 42 °C and 3 times for
5 min with 0.1-SSC at room temperature. Slides were
dried by centrifugation for 2 min at 2,000 rpm. Hy-
bridized slides were scanned using the GenePix
4,000A scanner (Axon Instruments, Foster City, CA,
USA). Arabidopsis RNA was used as a reference for
RNA labelling. Images were analysed using
GENEPIX PRO 3.0 (Axon Instruments). Spots
showing no signal or obvious defects were accord-
ingly flagged by GENEPIX PRO and excluded from
the analysis. Local background was subtracted from
the remaining spots, and then spots with fluorescence
intensity in both channels of < 1,000 were stringent-
ly flagged as absent. The background level for a typ-
ical array was of 67.5 (SD, 145.2) for the Cy5 chan-
nel and of 182.7 (SD, 305.4) for Cy3 channel. Maxi-
mum fluorescence intensity is at about 65,500 in both
channels, and arrays were scanned ensuring that <
1% of the total number of spots measured on the slide
had median intensities close to maximal. Ratios of
net fluorescence from the Cy5-specific channel to the
net fluorescence from the Cy3-specific channel were
calculated for each spot, representing tumour mRNA
expression related to the corresponding non-tumour
salivary gland tissue. A normalization factor was es-
timated from ratios of median by GENEPIX PRO.
Cy5:Cy3 expression ratios were then logtransformed
(base 2) and normalized, for each different array, by
adding the log2 of the respective normalization fac-
tor to the log2 of the ratio of medians for each spot
within the array, so that the average log-transformed
ratio was equal to zero. The threshold for significant
RNA expression changes (3.0-fold; i.e, ~ 1.5 on the
log2 scale) was established as 3 times the SD of an
assay, where the same RNA sample was indepen-
dently retrotranscribed and labelled with both cya-
nines. DNA spots present in at least 75% of the ar-
rays (5,681 spotted cDNAs) and with expression ra-
tios higher than the above-defined threshold, in at
least one array, were selected for the clustering
analysis (4,434 spotted cDNAs). To select the probes
that distinguish between two sample groups (e.g,
pleomorphic adenoma versus Warthin’s tumour), we
developed a programme performing two statistical
tests, t test and log likelihood. Log likelihood was de-
fined as the difference between the mean of each
probe in the two groups. To perform multiple t test-
ing correction, the Benjamini and Hochberg proce-
dure, as modified by Storey and Tibshirani 11, was ap-
plied. Briefly, it controls the pFDR, defined as the
proportion of probes expected to be identified by
chance (assuming probes are independent) relative to
the total number of probes called significant. This
procedure provides a good balance between discov-
ery of significant spots and protection against false
positives, because occurrence of the latter is held to a
small proportion of the list. A balanced bootstrap
analysis with 10,000 permutations was, therefore, ap-
plied to the tests to define the number of expected
false positives by chance. Expression tables were
analysed by using hierarchical clustering, PCA, and
similarity searches tools in JExpress v.2.1.5 Variance
normalization across the expression table was per-
formed only prior to similarity search to identify
probes with a similar expression pattern and was ob-
tained by normalizing the mean and then multiplying
each vector by a scalar so that its variance becomes
unity.
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Table I. Differentially expressed genes in salivary gland tumours.
After t test selection, as explained in Result and Discussion, the gene graphs were individually confirmed by using JExpress. In
this table, a selection of genes with the most highly significant t test values is reported. The complete tables can be found at
the web site.
Clone Gene bank Name Sample groupsa t test
Genes up-regulated in salivary gland tumours
279762 N48348 CEBPD pleo vs. wart 14.86
297460 W03635 RER1 pleo vs. wart 14.4
298792 W05091 KIAAO105 pleo vs. wart 12.72
259563 N41755 MYO7A pleo vs. nt 11.96
320698 W32039 DJ37E16.5 pleo vs. nt 11.41
309842 N94626 SNRPD2 pleo vs. wart 11.15
280943 N47576 TSLP pleo vs. wart 10.71
469566 AA027104 SLC3A1 pleo vs. wart 10.53
281588 N47992 MTP pleo vs. wart 10.42
114869 T87398 C5 pleo vs. wart 10.37
154604 R55493 PLVAP pleo vs. nt 10.2
322111 W37664 SLC25A20 pleo vs. wart 10.04
286970 N67453 CDKN1A pleo vs. wart 9.92
285638 N66473 HNRPA3 pleo vs. nt 9.82
109931 T84450 LOC51651 wart vs. nt 9.59
112468 T85888 DKFZP564O043 pleo vs. nt 9.46
32194 R17332 KIAA0564 pleo vs. nt 9.07
297460 W03635 RER1 pleo vs. nt 8.89
322111 W37664 SLC25A20 pleo vs. nt 8.08
114869 T87395 C5 pleo vs. nt 7.95
503523 AA131279 LMOD1 pleo vs. nt 7.69
212698 H69644 LOC51266 wart vs. nt 7.49
27679 R13006 GDA wart vs. nt 7.44
162251 H25971 DKFZp434G171 wart vs. nt 7.33
195560 R91819 PIK3R2 wart vs. nt 7.11
116851 T93608 STAM2 wart vs. nt 6.93
146355 R79518 MCAM wart vs. nt 6.9
41067 R56098 FREQ wart vs. nt 6.8
207669 H62271 LGP1 wart vs. nt 6.68
109863 T88721 EMP2 pleo vs. wart 5.74
271009 N42817 COX6C pleo vs. nt 5.72
321607 W32908 FOXO1A at vs. nt 5.6
308119 N92360 NFATC3 wart vs. nt 5.5
180257 R84726 ADORA1 pleo vs. wart 5.48
201990 R99333 KIAA1733 at vs. nt 5.23
501817 AA127953 HHEX at vs. nt 5.18
116844 T93783 FLJ13605 wart vs. nt 5.04
278649 N66214 NPEPPS at vs. nt 4.91
321269 W52940 MIL1 at vs. nt 4.75
446261 AA203732 CHP at vs. nt 4.7
358848 W94646 ITGAE wart vs. nt 4.24
109863 T88721 EP2 pleo vs. nt 4.16
Genes down-regulated in salivary gland tumours
42553 R61223 CAMK2 wart vs. nt -12.13
242058 H93330 SLC9A3R1 wart vs. nt -11.59
152489 R62399 MGC11352 wart vs. nt -9.43A. PASTORE, ET AL.
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Table. I. Continued
After t test selection, as explained in Result and Discussion, the gene graphs were individually confirmed by using JExpress. In
this table, a selection of genes with the most highly significant t test values is reported. The complete tables can be found at
the web site.
Clone Gene bank Name Sample groupsa t test
33862 R19859 EST pleo vs. wart -8.84
46743 H10327 RAP1B wart vs. nt -8.74
132026 R24904 PP1665 wart vs. nt -8.64
29961 R14696 FLJ12438 wart vs. nt -8.52
111650 T84578 CDC37 wart vs. nt -8.16
133326 R26844 EST wart vs. nt -8.13
265082 N30528 PPARD wart vs. nt -8.11
143341 R74281 PPP4C wart vs. nt -8.06
289002 N59818 HRIHFB2436 wart vs. nt -8.04
33862 R19859 EST pleo vs. nt -7.98
148698 H12850 EST pleo vs. nt -7.97
129794 R16987 SEC8 wart vs. nt -7.94
207992 H60458 ACOX2 pleo vs. wart -7.64
488555 AA047136 EST pleo vs. wart -7.56
49961 H29294 FLJ20364 pleo vs. wart -7.54
Genes up-regulated in salivary gland tumours
36318 R21064 KIAAO118 pleo vs. nt -7.52
241224 H91140 FLJ179 pleo vs. wart -7.32
66513 T66987 EST pleo vs. wart -7.28
39241 R51610 EST pleo vs. nt -7.14
136872 R36627 11-Oct pleo vs. wart -7.06
195560 R91819 PIK3R2 pleo vs. wart -7.05
236338 H61357 TP53 pleo vs. wart -7.01
132550 R25899 HNRPD pleo vs. nt -6.87
130426 R21806 EST pleo vs. nt -6.86
129794 R16987 SEC8 pleo vs. nt -6.65
380794 AA054151 OXA1L pleo vs. nt -6.41
146858 R80974 WEE1 wart vs. nt -6.26
178468 H47026 MGAT3 pleo vs. nt -6.21
140878 R67235 BAT1 pleo vs. nt -6.17
286050 N64281 EST at vs. nt -6.01
180257 R84726 ADORA1 wart vs. nt -5.73
150673 H02088 EST at vs. nt -5.57
36318 R21064 KIAAO118 at vs. nt -5.52
152489 R62399 MGC11352 at vs. nt -5.49
46743 H10327 RAP18 at vs. nt -5.41
178468 H47026 MGAT3 at vs. nt -5.36
380794 AA054151 OXA1L at vs. nt -5.35
375693 AA033736 AD037 at vs. nt -5.28
179383 H50403 FLJ20793 at vs. nt -5.19
134887 R32270 EMP2 wart vs. nt -4.61
147839 R81839 TXK at vs. nt -3.16
a at: all tumours; nt: non-tumor; pleo: pleomorphic adenoma; wart: Warthin’s tumour.Results
We compared the expression profiles of 12 salivary
gland tumours and four normal tissue samples by hy-
bridization to microarrays containing 19,200 cDNAs.
As the arrays shared a common normal tissue refer-
ence made of a pool of 8 non-tumour salivary glands,
different from those used as test samples, the samples
could be compared to identify gene expression pat-
terns correlated with clinical features of the tumours.
We used hierarchical clustering 12 to look at the vari-
ation in gene expression between tumours. A cluster-
ing analysis was performed by using the selected
4,434 spotted cDNAs, as described in Materials and
Methods, corresponding to 2,333 distinct Unigene
clusters present in 75% of the arrays and with
Cy5:Cy3 expression ratios that varied at least 3.0-
fold in at least one array. Using the t test, we then at-
tempted to identify gene expression alterations dif-
ferentiating the tumours from normal samples. t test
selected 713 spotted cDNAprobes (p < 0.01, average
t test significant spots in bootstrap, 91.82; pFDR,
0.05) corresponding to 486 distinct Unigene clusters.
Clustering, based on the 486-probe set, correlated
very well with the tumour histotypes, with the sole
exception of the mucoepidermoid carcinoma (Fig. 1).
Warthin’s tumours were the most distant branch, with
the non-tumour salivary glands in a separate branch
from that of the pleomorphic adenoma. The single
case of cell carcinoma, developed from a pleomor-
phic tumour, correctly clustered within the pleomor-
phic adenoma group. Differentially expressed can-
cer-associated genes, with the most highly significant
t test values 5 are outlined in Table I. Using a similar-
ity search with Euclidean distances on the variance
normalized expression table, as obtained using the
corresponding JExpress plugin, we identified genes
with coherent expression patterns to those of some
genes selected by the t test (Fig. 2). Interestingly,
among gene subsets that display expression patterns
coherent with FOXO1A, there are the PAX1, homolo-
gous to the FOX fused gene described above, a nov-
el Bcl-2 homologue (MIL1 or Bcl-rambo), and the 7b
and 7c subunits of cytochrome c oxidase (COX7B,
COX6C). Using semiquantitative reverse transcrip-
tion, we confirmed the expression levels of OTF1,
Wee1, and EMP2 (data not shown). Furthermore, we
identified a number of up- and down-regulated Ex-
pressed Sequence Tags (ESTs), which suggest the in-
volvement of a large number of genes that are not yet
functionally characterized in salivary gland tumours.
Defined subsets of clones that most strongly defined
the division of biopsies by histotype were identified
using the t test. When we applied this test to compare
each tumour to non-tumour samples, we selected 599
cDNA elements differentially expressed (p < 0.01,
average t test significant spots in bootstrap, 49.95;
pFDR, 0.04) in pleomorphic adenoma and 2586 ele-
ments (p < 0.01, average t test significant spots in
bootstrap, 5.73; pFDR, p < 0.001) specifically ex-
pressed in Warthin’s tumours. A total of 1198 clones
were differentially expressed (p < 0.001, average t
test significant spots in bootstrap, 0.13; pFDR, p <
157
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Fig. 1. Clustering of 713 spotted cDNA probes corre-
sponding to 486 Unigene clusters, selected by t test,
that were differentially expressed in salivary gland tu-
mours (p < 0.01, mean t test significant spots in boot-
strap, 80.4; pFDR, 0.04). Rows, cDNA probes; columns,
individual patient samples. Dark grey: probe over-ex-
pression; light grey: under-expression.0.001) in pleomorphic adenoma when compared with
Warthin’s tumour, of which 479 are over-expressed
in Warthin’s, whereas 719 are over-expressed in
pleomorphic denoma. The specificity of clone ex-
pression is shown in Table I. Finally, we selected a
subset of clones that most strongly defined the divi-
sion between malignant and benign lesions. Using
the log likelihood test, and as log2 threshold a value
of 1.5, corresponding to 3X SD from mean, we iden-
tified 16 Unigene clusters differentiating this malig-
nant clear cell carcinoma from its related benign
pleomorphic adenoma (p < 0.01, as determined by
bootstrap distribution). Because, as shown by hierar-
chical clustering (Fig. 1), Warthin’s tumour was very
divergent from the other biopsies, we then compared
the mucoepidermoid carcinoma to all the other sam-
ples after the exclusion of Warthin’s tumour samples.
Using the t test, we selected 57 cDNA probes (p <
0.01). Among the relevant genes repressed in mu-
coepidermoid carcinoma, there is the PSG11 member
of the carcinoembryonic antigen family and two
genes involved in apoptosis, CIDEB and ADORA1.
CIDEB or cell death-inducing DFFAlike effector b, is
involved in induction of apoptosis by DNA damage
19, and ADORA1, adenosine A1 receptor, is involved
in induction of apoptosis by extracellular signals. In-
terestingly, these genes are repressed only in mu-
coepidermoid carcinoma. FLJ10355, which is over-
expressed in the mucoepidermoid carcinomas, is also
over-expressed in the other malignant tumour clear
cell carcinoma and not expressed in the benign tu-
mours. FLJ10355 has some homology to Bcl9, a
gene translocated in some B-cell malignancies with
abnormalities of 1q21 18 and with no recognizable
protein motifs or significant homologies to any other
known proteins.
These data have been partially already published on
ref. 20.
Discussion and conclusions
The list of up- and down-regulated genes in most
salivary gland tumours include known genes in-
volved in neoplasia, members of signal transduction
pathways, transcription factors, oncogenes, and tu-
mour suppressor genes, cell cycle regulator, and
genes that encode protein involved in cellular me-
tabolism and adhesion. Forkhead box O1A
(FOXO1A) and PAX1 are present among up-regulat-
ed transcription factors. Fusion of forkhead box O1A
with PAX3, a PAX1-related gene, is associated with
solid tumour rhabdomyosarcoma. Over-expression
of the fusion protein activates the transcription of an-
ti-apoptotic protein Bcl-XL 12, capable of suppress-
ing cell death pathways by blocking the release of
cytochrome c from mitochondria and the caspase
protease cascade. Cytochrome c oxidase down-regu-
lation, alongside cytochrome c release to the cytosol,
was found to be present in Bax-induced growth ar-
rest 13. Over-representation of this gene subset sug-
gests that the activation of mechanisms that block
apoptosis is a major characteristic of tumour pro-
gression in salivary glands. One of the very few
genes consistently different in every tumour is
OTF1, highly expressed in non-tumour salivary
glands and under-expressed in all tumours. OTF1
protein binds specifically its POU domain to octamer
DNA motifs present in the promoters of several
genes and regulates their expression. In addition,
OTF1 participates in the cellular response to DNA
damage and is involved in the regulation of stress-in-
ducible genes 14. The identification of a number of
up- and down-regulated ESTs suggests the involve-
ment of a large number of genes that remain to be
functionally characterized in salivary gland tumours.
The many clones associated with Warthin’s tumour
are probably related to the presence of lymphoid
stroma in the affected glands, because some of the
selected genes are T-cell specific (i.e, NFATC3 and
ITGAE, an integrin preferentially expressed on in-
A. PASTORE, ET AL.
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Fig. 2. Clones with expression patterns coherent to pro-
minent tumour-associated genes, selected by using si-
milarity search with Euclidean distances on variance nor-
malized expression patterns.159
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traepithelial lymphocytes). Plag1, a gene that is of-
ten rearranged in pleomorphic tumour 19, surprising-
ly, is significantly over-expressed in Warthin’s tu-
mour (p < 0.01). In the Plag1 expression pattern
group (Fig. 2), other genes present are: PLK1, pro-
granulin, the elevated expression of which confers a
transformed phenotype on epithelial cells, including
anchorage independence in vitro and growth as tu-
mours in nude mice 15; hypothetical protein
FLJ13605 containing a tetra-tricopeptide repeat TPR
domain, which forms scaffolds to mediate protein-
protein interactions and often the assembly of multi-
protein complexes and has a spatial arrangement of
α-helices similar to those within 14-3-3 proteins; αL
subunit of integrin leukocyte function antigen-1, a
membrane glycoprotein that functions in cell-cell ad-
hesion by heterophilic interaction with intercellular
adhesion molecule 1; and polo-like serine/threonine
kinase PLK1 and TXK, a member of the Tec nonre-
ceptor subfamily of Src protein tyrosine kinases. We
identified only 16 Unigene clusters differentiating
the probe of malignant clear cell carcinoma from its
related benign pleomorphic adenoma. On the con-
trary, this clear cell carcinoma differed from the
Warthin’s tumours on account of a much larger num-
ber of cDNA elements (1,315), as expected for these
two non-related tumours, whereas 133 elements
were different from the non-tumour reference pool.
Genes differentiating this clear cell carcinoma from
its related benign tumour pleomorphic adenoma in-
clude myelin transcription factor 1-like, huntingtin,
ubiquitin specific protease 9, and FLJ10355 5.
In summary, the results show gene expression alter-
ations common to all tumours and unique to each be-
nign and malignant tumour. A larger epidemiological
study is necessary to determine whether expression
levels of the selected genes can be used as prognos-
tic indicators or whether additional genes need to be
included in the analysis. Finally, the numerous ESTs
of unknown function we identified could also be-
come useful as tumour markers and represent a set of
novel tumour-associated genes.
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